Moertel C G, Schutt A J, Hahn R G, O'Fallon J R
Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):554-7. doi: 10.1002/cpt1975185part1554.
The clinical antiemetic effect of bezquinamide by oral route at a dosage of 100 mg 3 times daily was evaluated by a controlled double-blind method in 183 studies of patients treated with 5-fluorouracil. The incidence of nausea and vomiting in benzquinamide-treated patients was equal to that in placebo-treated patients and significantly higher than that in patients treated with prochlorperazine, 10 mg 3 times daily. Sedation was the only significant side effect observed, and this occurred at essentially equal rates in benzquinamide- and prochlorperazine-treated patients.
采用对照双盲法，在183例接受5-氟尿嘧啶治疗的患者研究中，评估了口服剂量为每日3次、每次100mg的苄喹酰胺的临床止吐效果。接受苄喹酰胺治疗的患者恶心和呕吐的发生率与接受安慰剂治疗的患者相当，且显著高于每日3次、每次10mg氯丙嗪治疗的患者。镇静是观察到的唯一显著副作用，在接受苄喹酰胺和氯丙嗪治疗的患者中发生率基本相同。
